Drug Overview

Decitabine and cedazuridine is an innovative oral fixed-dose combination medication specifically designed to treat certain blood cancers and disorders like myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This combination brings together decitabine, a powerful hypomethylating agent that reactivates silenced genes in cancer cells to help restore normal blood cell production, and cedazuridine, a cytidine deaminase inhibitor that protects decitabine from rapid breakdown in the digestive system. This breakthrough allows patients to receive the same effective treatment as intravenous decitabine but in convenient tablet form at home, eliminating the need for frequent hospital visits and IV infusions that can disrupt daily life.

Unlike traditional chemotherapy drugs that indiscriminately kill fast-growing cells throughout the body—often leading to severe hair loss, nausea, and prolonged recovery—this epigenetic therapy works more gently at the molecular level. It helps abnormal blood cells mature into healthy ones and slows disease progression without the intense toxicity of high-dose regimens. This makes it especially valuable for older adults, frail patients, or those with other health conditions who cannot tolerate aggressive treatments like stem cell transplants or intensive induction chemotherapy. The simple once-daily tablet schedule for 5 consecutive days every 4 weeks integrates seamlessly into everyday routines, offering patients greater independence while delivering clinically equivalent results to hospital-based IV therapy.

Generic Name: Decitabine and cedazuridine.
US Brand Name: Inqovi®.
Drug Class: Hypomethylating agent (decitabine) + cytidine deaminase inhibitor (cedazuridine) / Oral epigenetic therapy combination.
Route of Administration: Oral tablets, taken by mouth on an empty stomach.
FDA Approval Status: FDA-approved for the treatment of adult patients with myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML).

What Is It and How Does It Work? (Mechanism of Action)

Decitabine and cedazuridine function synergistically: decitabine targets cancer at the epigenetic level by altering DNA methylation patterns that silence protective genes, while cedazuridine ensures decitabine survives the harsh gastrointestinal environment to reach therapeutic blood levels when swallowed as a pill. Without cedazuridine, stomach acids and liver enzymes like cytidine deaminase (CDA) would rapidly degrade oral decitabine into inactive forms, making IV delivery necessary—cedazuridine changes that equation entirely.

At the molecular level, once absorbed, decitabine is phosphorylated inside cells by deoxycytidine kinase to form decitabine triphosphate (S)-5-aza-2′-deoxycytidine-5′-triphosphate. During the S-phase of the cell cycle, DNA polymerase incorporates this analog into newly synthesized DNA strands in place of cytidine. DNA methyltransferase 1 (DNMT1), the maintenance methylase, then covalently binds to the incorporated decitabine at carbon-5, attempting methylation. However, this creates an irreversible covalent adduct that sequesters and depletes DNMT1. Subsequent DNA replications produce hemimethylated and unmethylated daughter strands, leading to progressive global hypomethylation, particularly at promoter CpG islands.

This demethylation reactivates epigenetically silenced tumor suppressor genes (e.g., p15INK4B, p21CIP1, p57KIP2, FOXO3), cell-cycle regulators, and pro-apoptotic factors, restoring differentiation, halting proliferation, and inducing programmed cell death (apoptosis) in leukemic blasts. Decitabine also directly damages DNA by stalling replication forks and generating double-strand breaks, activating ATM/ATR-p53 pathways. Cedazuridine selectively inhibits CDA in the gut mucosa and liver, boosting systemic decitabine exposure 5-10-fold to match IV pharmacokinetics precisely. This oral equivalence preserves decitabine’s immune-modulatory effects, upregulating MHC class I, tumor antigens, and PD-L1 for better immune recognition. The combination thus delivers sustained low-dose epigenetic reprogramming plus cytotoxic stress, ideal for chronic disease control in MDS/CMML.

FDA-Approved Clinical Indications

Oncological uses (FDA-approved)

Myelodysplastic syndromes (MDS) in adults, encompassing previously untreated patients as well as those with intermediate-1, intermediate-2, or high-risk disease according to the Revised International Prognostic Scoring System (IPSS-R).
Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myeloproliferative overlap syndrome responsive to hypomethylating therapy.

Non-oncological uses

There are currently no FDA-approved non-cancer (non-oncological) uses for decitabine and cedazuridine. Its clinical development and regulatory approvals concentrate exclusively on hematologic malignancies and related bone marrow disorders.

Dosage and Administration Protocols

Each fixed-dose tablet delivers 35 mg decitabine precisely combined with 100 mg cedazuridine. Patients take one tablet orally once daily for 5 consecutive days (days 1 through 5), followed by 23 days off treatment, repeating every 28-day cycle. Tablets must be swallowed whole—not crushed, chewed, or dissolved—and taken at least 1 hour before or 2 hours after food with 8 ounces of water only to optimize absorption.

Feature	Description
Standard adult dose	One oral tablet containing 35 mg decitabine + 100 mg cedazuridine, once daily.
Frequency of administration	Once daily on days 1-5 of each 28-day cycle; cycles repeat indefinitely if clinical benefit persists.
Route of administration	Oral tablets swallowed whole on an empty stomach with water (no food 1 hour before/2 hours after).
Typical treatment duration	4-12+ cycles (several months to years), guided by blood count responses, transfusion independence, and disease stability.
Dose adjustments (renal/hepatic insufficiency)	No dose modification needed for mild-moderate renal impairment (CrCl ≥30 mL/min) or hepatic dysfunction (Child-Pugh A/B). For severe myelosuppression, interrupt or reduce to half-tablet equivalents; hold in end-stage renal disease (CrCl <30 mL/min) or severe liver failure (Child-Pugh C). Frequent blood count monitoring essential.

If a dose is missed or vomiting occurs immediately after swallowing, skip it—do not double the next dose. Cycles may delay 1-2 weeks for count recovery.

Clinical Efficacy and Research Results

Pivotal phase 3 ASCERTAIN trial (NCT02103478, 2020-2021 results) established pharmacokinetic/bioequivalence to IV decitabine, with comparable clinical complete response (CR) or marrow CR rates of 20-25% and overall response rates (ORR) of 40-50% in higher-risk MDS. Median overall survival surpassed 18 months, mirroring IV outcomes while enabling home administration. Transfusion independence achieved in 30-40% lasting 6-12 months, significantly reducing healthcare burden.

Real-world evidence from 2022-2025 registries confirms durability, with CMML subsets showing >50% disease stabilization delaying AML transformation. Frontline AML combinations with venetoclax yield 60-80% CR rates in unfit elderly patients, extending median survival >16 months versus 7-10 months for decitabine monotherapy. Patient-reported outcomes highlight superior convenience (95% preference over IV) and quality-of-life gains in fatigue, mobility, and emotional well-being scores. Subgroup analyses favor IPSS-R high-risk disease, supporting guideline inclusion for oral HMA preference.

Safety Profile and Side Effects

Black Box Warning

Decitabine and cedazuridine causes profound myelosuppression with severe neutropenia, thrombocytopenia, and anemia, elevating risks of fatal infections, hemorrhage, and transfusion dependence. Embryofetal toxicity prohibits pregnancy use—verify negative pregnancy test and counsel contraception. Mandatory serial complete blood counts required.

Common side effects (>10%)

Fatigue or asthenia (most prevalent).
Neutropenia/thrombocytopenia (dose-limiting).
Constipation, nausea, or diarrhea.
Pyrexia (fever).
Back pain or arthralgia.
Dyspnea or cough.

Serious adverse events

Febrile neutropenia or sepsis.
Major hemorrhage (GI, intracranial).
Differentiation syndrome (fever, dyspnea, hypotension).
Pneumonitis or pulmonary edema.
Cardiac arrhythmias or acute kidney injury.

Management strategies

Prophylactic antimicrobials (levofloxacin, acyclovir, fluconazole) during neutropenia; hospitalize fever ≥100.4°F (38°C).
Preemptive antiemetics (ondansetron 8 mg), hydration (2-3 L/day), and senna/docusate for constipation.
G-CSF (filgrastim 5 mcg/kg) post-cycle 1 if ANC <500; transfusions for platelets <10k or hemoglobin <7 g/dL.
Bronchoscopy/CT chest for respiratory decline; hold cycles for grade 3+ non-hematologic toxicity.
Urgent evaluation for melena, hematuria, chest pain, confusion, or uncontrolled bleeding.

Connection to Stem Cell and Regenerative Medicine

Oral decitabine/cedazuridine serves as effective bridge therapy to allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk MDS/CMML by achieving 50-60% blast clearance while preserving normal hematopoietic stem cell reserves. 2022-2025 multicenter studies report superior transplant readiness versus supportive care, with post-HSCT relapse rates 20-30% lower due to sustained hypomethylation enhancing graft-versus-leukemia (GvL) effects.

Maintenance dosing post-HSCT (cycles 1-12) sustains donor chimerism >95% and reduces minimal residual disease, improving 2-year leukemia-free survival to 60-70%. Venetoclax combinations optimize stem cell mobilization (CD34+ yields >2×10^6/kg), facilitating haploidentical or umbilical cord options. The outpatient-friendly oral format cuts pre-HSCT hospitalizations by 40%, accelerating time-to-transplant while minimizing infectious complications. Immunotherapy synergies (azacitidine + PD-1 blockade) further amplify GvL, positioning this regimen central to modern transplant paradigms for poor-prognosis patients.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

Comprehensive baseline CBC with manual differential, reticulocyte count.
CMP including LFTs, renal panel, LDH, uric acid (tumor lysis risk).
Bone marrow biopsy/aspirate with cytogenetics, flow cytometry for blasts.
ECG, echocardiogram (EF ≥50% required).
HBV/HCV/CMV serologies; pregnancy test (serum β-hCG).

Precautions during treatment

Strict adherence to empty-stomach timing (no food/drink except water 1 hr before/2 hr after).
Dual contraception (hormonal + barrier) for males/females during therapy + 6 months post.
Infection avoidance: no fresh produce, crowds, sick contacts; influenza/pneumococcal vaccines pre-start.
Daily temperature monitoring; oral care with bicarbonate rinses.

“Do’s and Don’ts” list

DO swallow tablets whole with 8 oz water only, exactly on empty stomach schedule.
DO premedicate with ondansetron 30-60 min prior; sip clear fluids if nauseated.
DO log daily CBC symptoms (fever, bruising, dyspnea) and report grade 2+ immediately.
DO attend weekly labs cycles 1-2, biweekly thereafter without exception.
DON’T crush/chew/dissolve tablets or take near meals—bioavailability drops dramatically.
DON’T ignore petechiae, melena, epistaxis, fever >100.4°F, or new cough—seek ER evaluation.
DON’T self-medicate with OTC NSAIDs/aspirin (bleeding risk) or herbal supplements.
DON’T assume transfusion independence equals cure—lifelong monitoring post-response essential.

Legal Disclaimer

The information provided in this guide is strictly for educational and informational purposes only and does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any specific therapy. Decitabine and cedazuridine (Inqovi®) is FDA-approved solely for designated MDS/CMML indications under qualified hematologist-oncologist supervision per NCCN/ESMO guidelines. Treatment suitability depends on individual factors including IPSS-R risk, comorbidities, performance status, and molecular profile.